Daiichi Sankyo seeks Japan nod for Inavir in flu prophylaxis
This article was originally published in Scrip
Executive Summary
Based on positive Phase III results reported earlier this year, Daiichi Sankyo has applied for the approval in Japan of the long-acting neuraminidase inhibitor Inavir (laninamivir octanoate hydrate) for the prevention of influenza infection.